StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Bank of America

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byBank of AmericaHorizon: NA (inferred 1 year)23 Jul 2026via NDTV Profit (Live)

Entry₹1,101Inferred
Target₹1,480
Total upside +34.42%
Stop lossNot given
CMP₹1,3525h ago
Active+22.80%+9.47%upside left 9 mo left
Follow Bank of America for new callsGet alertsWatch DRREDDY for new buy/sell callsGet alertsSee 22 other Long-term calls on DRREDDYSee 411 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Oct, 9:25 pm IST
18 supporting8 neutral15 opposing
Supports the BUY call (18)

2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·27 Oct · 3d ago

Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside

NewsNdtv-Profit·26 Oct · 4d ago

(opens in new tab)

8 other SEBI-registered advisors have active long-term BUY calls on this stock, with 5 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · 4d ago

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 1w ago

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (8)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (15)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·30 Oct · today

6 other SEBI-registered advisors have active long-term SELL calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · 4d ago

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 1w ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 1w ago

(opens in new tab)

Dr. Reddy's reported Q2 FY27 consolidated revenue of Rs 86.7 billion (down 1.5% YoY) and profit after tax of Rs 9.25 billion (down 36% YoY), impacted by lower lenalidomide sales in North America.

NSE · Outcome of Board Meeting·23 Oct · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Bank of America

Every call and its outcome